Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
The first study to demonstrate an association between therapeutic radiation dose to the large bowel and colorectal cancer
Evidence for efficacy is based on the results from the TROPiCS-02 study
Findings from the ASTRUM-007 study
Updated disease-free survival data at the protocol-specified maturity of the ADAURA study
Evidence for efficacy is based on the results from the BRUIN study
Genomic features of HRD, PIK3CA mutations with copy number amplifications, and copy number amplifications are enriched in young women
Findings from the genomic profiling of ctDNA in patients included in the STING precision medicine study
FDA also approved the Guardant360 CDx assay as a companion diagnostic
New measure of tumour mutational burden based on genomic regions unlikely to undergo loss
Findings from a phase II clinical study of combined PD1, BRAF and MEK inhibition
Evidence for efficacy is based on the results from the KEYNOTE-091 study
Findings from a large cohort of patients with advanced non-small cell lung cancer demonstrate substantially different gain in survival by age
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
